Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. (NTRA) reported that Solomon Moshkevich, its President, Clinical Diagnostics, sold a total of 18,160 shares of common stock in early September 2026. On September 1, 2026, he sold 3,000 shares in multiple transactions pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024, at weighted average prices between $319.29 and $322.11 per share. On September 2, 2026, he sold 15,160 shares at $326.89 per share to satisfy tax withholding and remittance obligations related to vesting RSUs, under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Natera, Inc. (NTRA) reported that Chief Executive Officer and President Steven Leonard Chapman sold 1,698 shares of common stock on September 1, 2026 in an open-market or private transaction at a price of $320.99 per share. After this sale, he directly holds 98,199 shares of Natera common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on December 11, 2023 and amended on December 2, 2024 and March 5, 2026.
Natera, Inc. (NTRA) officer Solomon Moshkevich filed a notice under Rule 144 indicating an intention to sell common stock. The planned sale covers 29,423 shares of common stock, acquired upon vesting of restricted stock units on August 25, 2023 as compensation for services rendered.
The planned sale date is September 1, 2026, with sales to be effected through a broker on NASDAQ. The notice also lists several prior sales of Natera common stock by Solomon Moshkevich during July and August 2026, providing share counts and aggregate sale proceeds for each transaction.
Natera, Inc. (NTRA) is the issuer of common stock for which Steven L. Chapman has filed a Rule 144 notice. The notice covers the potential sale of 1,698 common shares
Natera, Inc. (NTRA) is the issuer for which executive officer Solomon Moshkevich filed a notice under Rule 144 to sell common stock. The notice covers a proposed sale of 3,000 shares of Natera common stock with an aggregate market value of $962,193.60, with an approximate sale date of 09/01/2026. The securities to be sold were acquired upon vesting of restricted stock and Performance Shares during the period from 01/14/2026 through 04/26/2026. In the prior three months, Moshkevich reported sales of Natera common stock on four dates totaling several thousand shares and over $2 million in proceeds.
Natera, Inc. (NTRA) reported insider equity activity by President and Chief Business Officer John Fesko. On August 6, 2026, he acquired 20,000 shares$0.006,517 shares$321.53Rule 10b5-1(c)
Natera, Inc. director and co-founder Jonathan Sheena reported selling 6,000 shares of Common Stock on August 10, 2026 in an open-market or private transaction at a weighted average price of $325.3237 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Sheena on December 12, 2025.
Following this sale, Sheena directly held 230,464 shares of Natera common stock. Additional indirect holdings of 18,032 shares are reported for each of Caraluna 1 Trust and Caraluna 2 Trust, which are held for the benefit of the trusts’ beneficiaries; Sheena disclaims beneficial ownership of those trust-held securities.
T. Rowe Price Associates, Inc. reports beneficial ownership of Natera, Inc. common stock on an amended Schedule 13G. The firm reports beneficial ownership of 9,021,825 shares, representing 6.3% of Natera’s common stock. It has sole voting power over 8,605,302 shares and sole dispositive power over all 9,021,825 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and it expressly denies such beneficial ownership.
Natera, Inc. executive chairman and director Matthew Rabinowitz reported selling 2,000 shares of Common Stock on August 7, 2026 at $320.90 per share, in an open-market or private transaction under a Rule 10b5-1 plan adopted December 5, 2025. After these transactions, he held 2,275,394 shares directly and 2,000 shares indirectly through his spouse.
Natera, Inc. director and co-founder Jonathan Sheena reported open‑market sales of a total of 9,150 shares of common stock on August 7, 2026, at prices between $308.4000 and $320.9000 per share. These sales were effected under a Rule 10b5‑1 trading plan adopted on December 12, 2025. The filing also lists 18,032 shares held in each of Caraluna 1 Trust and Caraluna 2 Trust for the benefit of trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.